Anti-ZNF277 monoclonal antibody

Pre-made anti-ZNF277 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ZNF277/ZNF277 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2830-Ab-1/ GM-Tg-hg-IP2830-Ab-2Anti-Human ZNF277 monoclonal antibodyHuman
GM-Tg-rg-IP2830-Ab-1/ GM-Tg-rg-IP2830-Ab-2Anti-Rat ZNF277 monoclonal antibodyRat
GM-Tg-mg-IP2830-Ab-1/ GM-Tg-mg-IP2830-Ab-2Anti-Mouse ZNF277 monoclonal antibodyMouse
GM-Tg-cynog-IP2830-Ab-1/ GM-Tg-cynog-IP2830-Ab-2Anti-Cynomolgus/ Rhesus macaque ZNF277 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2830-Ab-1/ GM-Tg-felg-IP2830-Ab-2Anti-Feline ZNF277 monoclonal antibodyFeline
GM-Tg-cang-IP2830-Ab-1/ GM-Tg-cang-IP2830-Ab-2Anti-Canine ZNF277 monoclonal antibodyCanine
GM-Tg-bovg-IP2830-Ab-1/ GM-Tg-bovg-IP2830-Ab-2Anti-Bovine ZNF277 monoclonal antibodyBovine
GM-Tg-equg-IP2830-Ab-1/ GM-Tg-equg-IP2830-Ab-2Anti-Equine ZNF277 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2830-Ab-1/ GM-Tg-hg-IP2830-Ab-2; GM-Tg-rg-IP2830-Ab-1/ GM-Tg-rg-IP2830-Ab-2;
GM-Tg-mg-IP2830-Ab-1/ GM-Tg-mg-IP2830-Ab-2; GM-Tg-cynog-IP2830-Ab-1/ GM-Tg-cynog-IP2830-Ab-2;
GM-Tg-felg-IP2830-Ab-1/ GM-Tg-felg-IP2830-Ab-2; GM-Tg-cang-IP2830-Ab-1/ GM-Tg-cang-IP2830-Ab-2;
GM-Tg-bovg-IP2830-Ab-1/ GM-Tg-bovg-IP2830-Ab-2; GM-Tg-equg-IP2830-Ab-1/ GM-Tg-equg-IP2830-Ab-2
Products NameAnti-ZNF277 monoclonal antibody
Formatmab
Target NameZNF277
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ZNF277 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2830-Ag-1Recombinant multi-species ZN277/ ZNF277/ NRIF4P protein


    Target information

    Target IDGM-IP2830
    Target NameZNF277
    Gene ID11179,246196,298977,702496,475289,101087144,508663,100070827
    Gene Symbol and Synonyms2410017E24Rik,NIRF4,NRIF4,Zfp277,ZNF277,ZNF277P
    Uniprot AccessionQ9NRM2
    Uniprot Entry NameZN277_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000198839
    Target ClassificationN/A

    The target: ZNF277, gene name: ZNF277, also named as NRIF4P, ZNF277. Predicted to enable RNA polymerase II cis-regulatory region sequence-specific DNA binding activity and metal ion binding activity. Predicted to act upstream of or within cellular response to hydrogen peroxide and regulation of cellular senescence. Predicted to be located in nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.